The Ayurvedic Evidence Atlas: Every Herb, Every Condition, Every Evidence Level

Dr. Meera Iyer — Wed, 08 Apr 2026 18:30:54 +0000

This Ayurvedic evidence atlas is a practical reference for checking how much modern human evidence supports a herb-condition pairing. It is a map of the literature, not a prescribing guide.

The ratings reflect evidence available through 16 June 2026 and apply only to the plant part, extract, formulation, population, and duration studied. The Ayurvedic Pharmacopoeia of India sets identity and quality standards; inclusion does not itself prove clinical efficacy.

How to Read the Evidence Levels

Pairings are graded conservatively, with replicated patient outcomes weighted above laboratory mechanisms, animal work, biomarkers, or historical use.

Strong: Several adequate randomized trials and consistent systematic reviews support a clinically meaningful benefit.
Moderate: Controlled trials or meta-analyses suggest benefit, but small samples, short follow-up, heterogeneous extracts, sponsorship, or bias reduce confidence.
Emerging: One or a few small human studies, pilot trials, surrogate outcomes, or mainly preclinical findings suggest a possible effect.
Traditional: The use is documented in Ayurvedic practice or official sources, but dependable modern human trials are inadequate.
Insufficient or mixed: Findings are conflicting, negative, weak, or too sparse for a positive conclusion.

No grade means “cure,” “equivalent to standard care,” or “safe for everyone.” Diagnosis, product quality, interactions, contraindications, and monitoring remain separate questions.

The Atlas: Herbs and Conditions

The tables retain pairings supported by traceable human research, an authoritative review, or a clearly identified traditional basis.

Ashwagandha (Withania somnifera)

The official pharmacopoeial drug is the dried mature root. Branded root extracts, root-and-leaf extracts, and raw powder are not interchangeable.

Condition	Evidence	Verified Interpretation
Stress and anxiety symptoms	Moderate	Meta-analyses report improvements in symptoms and cortisol, but heterogeneity and limited long-term safety prevent a strong rating.
Sleep quality or insomnia	Moderate	Five randomized trials involving 400 participants found a small overall benefit, greatest among people with insomnia.
Male infertility	Emerging	A small pilot improved semen parameters but did not establish pregnancy or live-birth benefit.
Muscle strength	Emerging	Small resistance-training trials reported gains with specific extracts; replication is limited.
Subclinical hypothyroidism	Emerging	One small eight-week trial improved thyroid indices. Thyrotoxicosis reports make self-treatment inappropriate.
Cognition or memory	Emerging	Small trials report selected improvements; larger independent studies are needed.
Cancer treatment	Insufficient	Anticancer claims remain mainly preclinical and cannot replace oncology care.

Turmeric and Curcumin (Curcuma longa)

Turmeric rhizome, concentrated curcuminoids, and enhanced-bioavailability products produce different exposures. Evidence for one cannot automatically be transferred to another.

Condition	Evidence	Verified Interpretation
Knee osteoarthritis	Moderate	Reviews suggest short-term pain and function improvement, but variable products and study quality do not establish universal equivalence to ibuprofen.
Inflammatory markers	Moderate	Meta-analyses report average CRP reductions; a biomarker change does not prove disease treatment.
Depressive symptoms	Emerging	Possible adjunctive benefit is reported, but samples are small and heterogeneous. Curcumin is not an antidepressant replacement.
Metabolic syndrome markers	Emerging	Pooled studies report modest lipid or glucose changes, without firm clinical-outcome evidence.
Ulcerative colitis maintenance	Emerging	One trial found fewer relapses when curcumin was added to standard therapy; confirmation is needed.
Cognition	Emerging	Small trials report selected benefits, while overall findings remain inconsistent.
Cancer treatment	Insufficient	The US National Cancer Institute finds evidence inadequate to recommend curcumin for cancer treatment.

Boswellia or Shallaki (Boswellia serrata)

Studies use differently standardized gum-resin extracts, so results should not be generalized to every Boswellia supplement.

Condition	Evidence	Verified Interpretation
Osteoarthritis	Moderate	A 2020 meta-analysis of seven trials and 545 patients found better pain, stiffness, and function, but studies were small and heterogeneous.
Bronchial asthma	Emerging	An older six-week double-blind trial was positive, without sufficient modern replication.
Inflammatory bowel disease	Insufficient or mixed	An active Crohn disease study was encouraging, but a later study did not demonstrate maintenance of remission.
Radiotherapy-associated cerebral edema	Emerging	A small randomized pilot reported reduced edema; this remains an oncology-supervised adjunct, not tumor treatment.

Triphala (Amalaki, Bibhitaki, and Haritaki)

Triphala is a three-fruit formulation. Results for one fruit, a cell culture, or a laboratory organism do not prove the same effect for the complete formula in patients.

Condition	Evidence	Verified Interpretation
Constipation	Emerging	Traditional use and small reports suggest a laxative role, but robust chronic-constipation trials are lacking.
Gut microbiome modulation	Emerging	The frequently cited 2017 publication is a narrative review, not a controlled human microbiome trial.
Plaque and gingivitis mouthwash	Moderate	Several short trials found reductions broadly comparable with chlorhexidine, although samples and preparations limit generalization.
Systemic antioxidant benefit	Insufficient	In-vitro antioxidant activity does not establish prevention or treatment of human disease.

Guduchi (Tinospora cordifolia)

Guduchi is promoted for immunity and metabolism, but clinical evidence is narrow. Published reports also associate Tinospora cordifolia products with acute liver injury.

Condition	Evidence	Verified Interpretation
Allergic rhinitis	Emerging	One placebo-controlled trial in 75 patients reported improvement; independent replication is limited.
General immunomodulation	Emerging	Most cited evidence concerns compounds, cells, or animals rather than clinical immune outcomes.
Type 2 diabetes	Insufficient	Evidence is mainly preclinical or weak and cannot replace established treatment or monitoring.
Fever	Traditional	Use for fever is traditional, but Guduchi alone is not an established treatment for an undiagnosed fever. Evidence for a multi-ingredient formula cannot be assigned to one ingredient.

Additional Herbs: Quick Matrix

Fixed “standard doses” are removed because dosing depends on authenticated species, plant part, extraction, formulation, indication, patient, and concurrent medicines.

Herb	Common Claim	Evidence	Verified Interpretation
Shatavari (Asparagus racemosus)	Lactation	Emerging	Small studies report lactation-related changes; evidence and breastfeeding safety data remain limited.
Brahmi (Bacopa monnieri)	Memory and attention	Moderate	A nine-trial meta-analysis found the clearest effect on speed of attention; dementia evidence is uncertain.
Piperine from Piper species	Bioavailability	Emerging	A small study increased curcumin exposure but did not prove better clinical outcomes or universal interaction safety.
Guggulu (Commiphora wightii/C. mukul)	Cholesterol	Insufficient or mixed	A JAMA trial did not lower cholesterol and found small LDL increases.
Yashtimadhu (Glycyrrhiza glabra)	Ulcer or gastritis	Insufficient	Evidence is inadequate; glycyrrhizin can cause serious blood-pressure, potassium, and cardiac effects.
Tulsi (Ocimum tenuiflorum)	Stress symptoms	Emerging	One eight-week trial was positive for a specific extract; independent replication is needed.
Amalaki (Phyllanthus emblica)	Lipid management	Emerging	Reviews suggest possible lipid changes, but trials remain limited and product-specific.
Neem (Azadirachta indica)	Acne or eczema	Traditional/insufficient	Evidence is mainly laboratory, topical, or preliminary; dependable support for internal treatment is lacking.

What This Atlas Reveals

The clearest short-term human signals here are Ashwagandha for stress or sleep symptoms, curcuminoid and Boswellia extracts for osteoarthritis symptoms, Bacopa for selected cognitive measures, and Triphala mouthwash for plaque and gingivitis. None justifies a cure claim.

Many results concern surrogate endpoints such as cortisol, CRP, glucose, thyroid indices, or semen parameters. These changes do not automatically prove durable remission, restored fertility, fewer complications, or longer survival.

Traditional use answers a different question from a randomized trial. The Pharmacopoeia and Formulary define official ingredients and quality standards; they do not certify clinical effectiveness for every promoted indication.

Cautions and Honest Gaps

The same limitations recur across most entries and should temper clinical interpretation and marketing.

Formulation mismatch: One standardized extract may not represent another extract, a decoction, or raw churna.
Short follow-up: Trials lasting weeks cannot establish long-term benefit, rare toxicity, or durable safety.
Small or sponsored studies: Positive pilots may overestimate benefit and often lack independent replication.
Specific risks: Ashwagandha may affect thyroid function and has rare liver-injury reports; bioavailable curcumin and Guduchi also have liver-injury signals; glycyrrhizin-containing licorice can cause serious adverse effects.
Quality variation: Authentication, contaminant limits, manufacturing controls, and testing matter, but a quality seal does not prove efficacy.
Interactions: Herbal products may interact with medicines and may be unsuitable during pregnancy, breastfeeding, childhood, surgery, liver disease, thyroid disease, autoimmune disease, or cancer treatment.

How to Use This Atlas

Practitioners should state the exact preparation studied, expected benefit, uncertainty, risks, and standard care that must not be delayed. A “moderate” rating supports a careful discussion, not automatic prescribing.

Consumers should treat “clinically studied,” “standardized,” “natural,” “detoxifying,” and “immune boosting” as incomplete unless the claim names the tested product, condition, outcome, and safety limits. Claims that an herb cures cancer, diabetes, thyroid disease, infertility, or inflammatory bowel disease exceed this evidence.

The responsible bridge between Ayurveda and modern research is accurate botanical identification, transparent grading, product-specific interpretation, safety screening, and revision as better trials appear.

Disclaimer: This page is educational and is not medical advice or a prescribing guide. Do not stop, replace, or delay treatment. Consult a qualified Ayurvedic practitioner and healthcare provider before using herbs, especially with prescription medicines, pregnancy, breastfeeding, or liver, thyroid, autoimmune, bleeding, fertility, psychiatric, or cancer concerns.

evidence levels – Ayurved Healing